title: The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
abstract: What is the correct use of established clotting factors, prothrombin complex concentrates (PCCs), and activated factor VII in bleeding complications of trauma, surgery, and old and new oral anticoagulants? How will new clotting factors, specifically the long-acting factors, change the hemostatic management of coagulation deficiency disorders? From bench to bedside, comparative coagulation studies and clinical trials of modified clotting factors are providing insights to help guide hemostatic management of congenital and acquired bleeding disorders. Comparative thrombin-generation studies and preclinical and clinical trials suggest that PCCs and fresh-frozen plasma are effective in reversing the anticoagulant effects of warfarin, yet there are few data to guide reversal of the new oral anticoagulants dabigatran and rivaroxaban. Although coagulation studies support the use of PCCs to reverse new oral anticoagulants, correlation with clinical response is variable and clinical trials in bleeding patients are needed. For congenital bleeding disorders, exciting new technologies are emerging from the bench. Data from clinical trials of molecularly modified coagulation factors with extended half-lives suggest the possibility of fewer infusions, reduced bleeds, and better quality of life in persons with hemophilia. Preclinical studies of other novel prohemostatic approaches for hemophilia and other congenital coagulation disorders include RNA interference silencing of antithrombin, monoclonal anti-tissue factor pathway inhibitor (anti-antibody, anti-tissue factor pathway inhibitor) aptamer, bispecific anti-IXa/X antibody, and fucoidans. Understanding the comparative coagulation studies of established prohemostatic agents, the pharmacokinetics of new long-acting clotting factors, and their correlation with bleeding outcomes will provide opportunities to optimize the hemostatic management of both congenital and acquired hemostatic disorders.
authors: 1Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA.
authors: Margaret V
authors: MV
authors: Ragni
mesh_terms: D000906:Antibodies / Q000627:therapeutic use; D000925:Anticoagulants / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000493:pharmacokinetics / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000069604:Dabigatran; D015942:Factor VIIa / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006207:Half-Life; D006467:Hemophilia A / Q000188:drug therapy*; D006470:Hemorrhage / Q000151:congenital / Q000188:drug therapy*; D006490:Hemostatics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009025:Morpholines / Q000493:pharmacokinetics / Q000627:therapeutic use; D034622:RNA Interference; D000069552:Rivaroxaban; D013876:Thiophenes / Q000493:pharmacokinetics / Q000627:therapeutic use; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000906:Antibodies; D000925:Anticoagulants; D001562:Benzimidazoles; D001779:Blood Coagulation Factors; D006490:Hemostatics; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; C025667:prothrombin complex concentrates; D000069552:Rivaroxaban; D015942:Factor VIIa; D000069604:Dabigatran